References in periodicals archive ?
The multinational, randomized phase III First-line Indolent Trial (FIT) evaluated the benefit and safety of a single infusion of Zevalin in patients with CD20-positive follicular non-Hodgkin's lymphoma who had achieved a partial response or a complete response after receiving standard first-line chemotherapy regimens.
ZEVALIN is in my opinion the most effective single drug available with an acceptable hematological toxicity profile for the treatment of patients with low-grade malignant follicular non-Hodgkin's lymphoma," said Anton Hagenbeek, M.
ZEVALIN (ibritumomab tiuxetan, injection for intravenous use) is indicated for the treatment of patients with previously untreated follicular non-Hodgkin's Lymphoma (NHL), who achieve a partial or complete response to first-line chemotherapy.
Genitope Corporation is conducting a pivotal phase 3 clinical trial using MyVax (R) Personalized Immunotherapy in previously untreated follicular non-Hodgkin's lymphoma patients.
Santos, Biovest's Vice President, Product Development & Regulatory Affairs, will present an overview of BiovaxID[R], a personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma and mantle cell lymphoma.
Genitope Corporation is conducting a pivotal phase 3 clinical trial using MyVax(R) Personalized Immunotherapy in previously untreated follicular non-Hodgkin's lymphoma patients.
Developed in collaboration with the National Cancer Institute, BiovaxID[R] is a patient-specific, cancer vaccine, demonstrating statistically significant Phase III clinical benefit by prolonging disease-free survival in vaccinated patients suffering from indolent follicular non-Hodgkin's lymphoma, confirming a previous positive Phase II study.
The FDA previously granted Orphan Drug Designation for BiovaxID for the treatment of indolent follicular non-Hodgkin's lymphoma.
July 25 /PRNewswire-FirstCall/ -- Genitope Corporation today announced that its independent Data Safety Monitoring Board (DSMB) reviewed the first planned interim analysis of data for efficacy in its pivotal Phase 3 clinical trial for treatment of follicular non-Hodgkin's Lymphoma (fNHL) and recommended that the trial continue as planned.
Biovest is also currently preparing to seek approvals for BiovaxID for the treatment of follicular non-Hodgkin's lymphoma.
Genitope Corporation is conducting a pivotal phase 3 trial using MyVax(R) Personalized Immunotherapy in previously untreated follicular non-Hodgkin's lymphoma patients.
prepare to exit from reorganization, it is a priority for us to attend and present at key industry and investor events to communicate the vital role that we envision for BiovaxID in potentially enhancing existing regimens for the treatment of indolent follicular non-Hodgkin's lymphoma and other B-cell blood cancers.